{
  "id": 19149417,
  "title": "Can-Fite reports patient cancer-free 10 years after trial",
  "url": "https://urgent.news/2026/11/09/can-fite-reports-patient-cancer-free-10-years-after-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-09T12:24:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/canfite-reports-patient-cancerfree-10-years-after-trial-93CH-5011682"
  },
  "original_language": "en",
  "account": "Ramat Gan, Israel - Can-Fite BioPharma Ltd., an Israeli biotech company, reported on Monday that a patient with advanced liver cancer participating in their completed Phase II trial of Namodenoson has now reached a ten-year overall survival rate and remains cancer-free. This patient had previously reported a complete response to the drug in November 2025.\n\nThe company initially announced a nine-year survival rate for this patient back in November 2025. Namodenoson, currently under evaluation in a randomized, double-blind, placebo-controlled pivotal Phase III study for advanced hepatocellular carcinoma in patients with Child-Pugh B7 cirrhosis, showed a survival rate for this patient that exceeded expectations based on the study's design assumptions, according to a September 2, 2026 announcement.\n\nThe Phase III study of Namodenoson remains blinded, and the survival data includes both patients who received the drug and those who received a placebo. The company plans to assess treatment-specific efficacy through a planned analysis.\n\nNamodenoson is a small, orally bioavailable drug that targets the A3 adenosine receptor. The drug has received Orphan Drug Designation in the U.S. and Europe, and Fast Track Designation as a second-line treatment for hepatocellular carcinoma from the U.S. Food and Drug Administration. Can-Fite BioPharma, a clinical-stage biotechnology company, is developing small molecule drugs targeting oncological and inflammatory diseases, with its lead drug Piclidenoson currently in a pivotal Phase III study for plaque psoriasis, with interim results expected in Q1 2027.",
  "summary": null,
  "key_points": [
    "Patient with advanced liver cancer achieved ten-year survival after Namodenoson trial.",
    "Namodenoson showed survival rate exceeding study assumptions in Phase III study.",
    "Can-Fite BioPharma developing small molecule drugs for oncological and inflammatory diseases."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}